Results 41 to 50 of about 12,405 (251)

Features of application of raltegravir in HIV-infected patients with different somatic pathologies

Журнал инфектологии, 2021
Purpose of the study. Evaluation of the efficacy, safety and tolerability of raltegravir regimens in HIV-infected patients with concomitant pathology in real clinical practice.Materials and methods.
N. V. Sizova, E. S. Obizhaeva, S. O. Mayorova   +2 more
doaj   +1 more source

Dissolution Enhancement of Raltegravir by Hot Melt Extrusion Technique

Iraqi Journal of Pharmaceutical Sciences, 2018
The objective of the study to develop an amorphous solid dispersion for poorly soluble raltegravir by hot melt extrusion (HME) technique. A novel solubility improving agent plasdone  s630 was utilized.
Ahmed S. Abdul Jabbar
doaj   +1 more source

Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir [PDF]

Antimicrobial Agents and Chemotherapy, 2015
ABSTRACT Raltegravir pharmacokinetics was studied in 20 patients included in the ANRS HC30 QUADRIH Study before and after addition of anti-hepatitis C virus (anti-HCV) quadritherapy, including pegylated-interferon–ribavirin and asunaprevir plus daclatasvir.
Aurélie Barrail-Tran, Corine Vincent, Eric Rosenthal, Jean-Michel Molina, Antoine Cheret, Valérie Furlan, Anne-Marie Taburet, Isabelle Rosa, Lionel Piroth   +8 more
openaire   +3 more sources

Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance.

PLoS ONE, 2019
Antiretroviral agents are approved in Japan based on non-clinical and clinical data reported from overseas. Neither the long-term tolerability nor the effectiveness of raltegravir or other integrase strand transfer inhibitors in Japan is known.
Naho Kuroishi, Asuka Watananbe, Ryuta Sakuma, Daniel J Ruzicka, Mitsuyoshi Hara   +4 more
doaj   +1 more source

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence

Frontiers in Microbiology, 2019
The human immunodeficiency virus type 1 (HIV-1) has several proteins of therapeutic importance, many of which are currently used as drug targets in antiretroviral therapy. Among these proteins is the integrase, which is responsible for the integration of
Lucas de Almeida Machado, Marcelo Ferreira da Costa Gomes, Ana Carolina Ramos Guimarães   +2 more
doaj   +1 more source

Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine.

AIDS (London), 2020
: Fat gain is reported in integrase-strand-transfer-inhibitors-exposed persons-living-with-HIV(PLWH). We investigated in 165 PLWH (117 men/48 women), included in the 96-week ANRS-163-ETRAL trial and switched to raltegravir/etravirine, the impact of sex ...
L. Assoumou, C. Racine, S. Fellahi, A. Lamazière, D. Farabos, L. Béniguel, J. Bastard, B. Fève, S. Gibowski, C. Katlama, D. Costagliola, J. Capeau   +11 more
semanticscholar   +1 more source

Efficacy and Safety of Raltegravir-Based Dual Therapy in AIDS Patients: A Meta-Analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2019
Background: The life expectancy for HIV-infected individuals has improved dramatically because of improvements in antiretroviral therapy (ART). Today, a simplified two-drug regimen enhances adherence and treatment satisfaction by reducing adverse effects.
Yinqiu Huang, Yinqiu Huang, Xiaojie Huang, Hui Chen, Hao Wu, Yaokai Chen, Yaokai Chen   +6 more
doaj   +1 more source

Phenotypic susceptibility of HIV-2 to raltegravir [PDF]

AIDS, 2011
Raltegravir is the first integrase strand transfer inhibitor approved for treating HIV-1 infection. Although emerging data suggest that raltegravir may also be useful for HIV-2 treatment, studies addressing the in-vitro susceptibility of HIV-2 to raltegravir are scarce, and the genetic pathways leading to raltegravir resistance in HIV-2 have not been ...
Nancy B. Kiviat, Papa Salif Sow, Robert A. Smith, Dana N. Raugi, Stephen E. Hawes, Geoffrey S. Gottlieb, James I. Mullins   +6 more
openaire   +3 more sources

Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

Journal of the Pediatric Infectious Diseases Society, 2020
Pharmacological interactions limit treatment options for children living with human immunodeficiency virus (HIV) and tuberculosis (TB). We found that 12 mg/kg twice daily raltegravir chewable tablets (administered after crushing) safely achieved ...
P. Krogstad, P. Samson, E. Acosta, J. Moye, Ellen Townley, Sarah Bradford, E. Brown, Kayla Denson, B. Graham, L. Hovind, Thucuma Sise, H. Teppler, S. R. Mathiba, L. Fairlie, J. Winckler, G. Slade, T. Meyers   +16 more
semanticscholar   +1 more source

Inhibition of OATP1B1/3 Rather Than UGT1A1 May Be the Major Cause of the Bilirubin Elevation After Atazanavir Administration

Clinical Pharmacology &Therapeutics, EarlyView.
Atazanavir has been reported to increase total serum bilirubin level up to ninefold. It is widely believed that the observed total bilirubin elevation is primarily due to UGT1A1 inhibition. However, UGT enzymes are well‐known as a low‐affinity and high‐capacity system, and the observed drug–drug interaction mediated by UGTs is usually less than twofold.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source